• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4595230)   Today's Articles (0)   Subscriber (49331)
Number Citation Analysis
26
Cardoso F, Piccart-Gebhart MJ, Rutgers EJ, Litière S, Van't Veer L, Viale G, Pierga JY, van den Berkmortel FW, Brain E, Gomez P, Goulioti T, Knox S, Luporsi E, Nitz U, Rubio IT, Stork L, Vuylsteke P, TRYFONIDIS KONSTANTINOS, Bogaerts J, Delaloge S. Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.516] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
27
Huober JB, Holmes EM, Baselga J, De Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith IE, Boyle FM, Xu B, Lecocq C, De La Pena L, Jackisch C, Gelber RD, Piccart-Gebhart MJ, Di Cosimo S. Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.512] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
28
Moreno-Aspitia A, Holmes EM, Jackisch C, De Azambuja E, Boyle FM, Hillman DW, Korde LA, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Lang I, Xu B, Smith IE, Barrios CH, Gelber RD, Baselga J, Piccart-Gebhart MJ. Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.502] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
29
Von Minckwitz G, Procter MJ, De Azambuja E, Zardavas D, Knott A, Viale G, Suter TM, Arahmani A, Rouchet N, Clark E, Benyunes M, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart-Gebhart MJ, Baselga J. APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.lba500] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
30
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017;389:1195-1205. [PMID: 28215665 PMCID: PMC5465633 DOI: 10.1016/s0140-6736(16)32616-2] [Citation(s) in RCA: 626] [Impact Index Per Article: 89.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Revised: 09/26/2016] [Accepted: 10/04/2016] [Indexed: 12/21/2022]
31
Cardoso F, Slaets L, de Snoo F, Bogaerts J, van 't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Russo L, Dell'Orto P, Viale G. Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd7-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
32
Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, Al-Sakaff N, Piccart-Gebhart MJ, de Azambuja E. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. J Clin Oncol 2016;35:878-884. [PMID: 28199174 DOI: 10.1200/jco.2015.65.7916] [Citation(s) in RCA: 98] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
33
Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JBAG, van Vugt MATM, de Vries EGE, Schröder CP, Fehrmann RSN. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. J Natl Cancer Inst 2016;109:2905892. [PMID: 27737921 DOI: 10.1093/jnci/djw192] [Citation(s) in RCA: 241] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Accepted: 07/25/2016] [Indexed: 12/20/2022]  Open
34
Saura C, De Azambuja E, Oliveira M, Dubsky PC, Zardavas D, Fesl C, Bardia A, Soberino J, Fornier MN, Boer K, Ng V, Fredrickson JO, Stout T, Singel S, Hsu JY, Piccart-Gebhart MJ, Baselga J, Gnant M. LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.tps613] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
35
Gingras I, Holmes EM, De Azambuja E, Nguyen DHA, Izquierdo MA, Zujewski JA, Inbar MJ, Naume B, Tomasello G, Gnant M, Moreno-Aspitia A, Piccart-Gebhart MJ, Azim HA. Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
36
Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol 2016;1:448-54. [PMID: 26181252 DOI: 10.1001/jamaoncol.2015.0830] [Citation(s) in RCA: 422] [Impact Index Per Article: 52.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
37
Di Cosimo S, Campbell C, Hazim HA, Curigliano G, Criscitiello C, Crescenzo R, de la Pena L, Piccart-Gebhart MJ, Eidtmann H, Baselga J, de Azambuja E. Abstract P6-01-04: Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-01-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
38
Zardavas D, Te Marvelde L, Milne R, Joensuu H, Moynahan ME, Hennessy B, Bieche I, Saal LH, Stal O, Iacopetta B, Dupont Jensen J, O'Toole S, Barbareschi M, Noguchi S, Lerma E, Wang Q, Piccart-Gebhart MJ, Sotiriou C, Michiels S, Loi S. Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.516] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
39
Azim HA, Nguyen B, Brohee S, Piccart-Gebhart MJ, Sotiriou C. The pattern of somatic mutations and chromosomal copy number variations (CNV) in young breast cancer (BC) patients (pts). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
40
Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes EM, Bria E, Denkert C, Eidtmann H, Sotiriou C, Loi S, Andre F, Untch M, Conte PF, Piccart-Gebhart MJ, Von Minckwitz G, Baselga J. Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.511] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
41
Liu MC, Rack B, Dueck AC, Hillman DW, Campion MB, Reinholz MM, Halling KC, Sotiriou C, Rothé F, Maetens M, Rouas G, Janni W, Wolff AC, Harris LN, Gralow JR, Pritchard KI, Ellard S, Le-Lindqwister NA, Boyle F, De Azambuja E, Piccart-Gebhart MJ, Ignatiadis M, Perez EA. Abstract P4-01-01: Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p4-01-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
42
Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Ann Oncol 2015;26:1494-500. [PMID: 25851628 DOI: 10.1093/annonc/mdv175] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Accepted: 03/20/2015] [Indexed: 01/30/2023]  Open
43
de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM. Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). J Clin Oncol 2014;32:2159-65. [DOI: 10.1200/jco.2013.53.9288] [Citation(s) in RCA: 171] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
44
Piccart-Gebhart MJ, Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Santillana S, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith IE, Boyle F, Xu B, Gomez HL, Gelber RD, Perez EA. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.18_suppl.lba4] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
45
Ades F, Rua Rodriguez Rochedo P, Metzger-Filho O, Werutsky G, Bines J, Zardavas D, De Azambuja E, Saini KV, Parent F, Piccart-Gebhart MJ, Frossard Pereira de Lucena A. A comparative analysis of the association between health expenditure and cancer survival in 168 countries. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.1591] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
46
De Greve J, De Brakeleer S, Desmedt C, Joris S, Sotiriou C, Piccart-Gebhart MJ, Pauwels I, Teugels E. Frequent BRCA1/2 and BARD1 germline mutations in triple-negative breast cancer patients. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.1107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
47
Fumagalli D, Jose V, Salgado R, Michiels S, Wilson TR, O'Brien C, Huw L, Rouas G, Criscitiello C, Pugliano L, Piccart-Gebhart MJ, Lackner MR, Loi S, Sotiriou C. Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.11060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
48
Andre F, Daly F, Azim HA, Agrapart V, Goulioti T, Pinto ACDCP, Saba C, Guitart M, Turner NC, Pierrat MJ, Loibl S, Chesnel T, Curigliano G, Loi S, Piccart-Gebhart MJ, Cortes J. FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.tps1134] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
49
Piccart-Gebhart MJ, Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Santillana S, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith IE, Boyle F, Xu B, Gomez HL, Gelber RD, Perez EA. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.lba4] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
50
Dueck AC, Hillman DW, Kottschade LA, Halyard MY, Sloan JA, Flickinger LM, Wolff AC, Harris L, Gralow J, Pritchard KI, Ellard S, Le-Lindqwister N, Boyle FM, De Azambuja E, McCaskill-Stevens WJ, Zujewski JA, Piccart-Gebhart MJ, Perez EA. Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.647] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
PrevPage 2 of 6 123456Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA